Showing results (51-60 of 93) with videos related to
Sort By:
Pageof 10
Thoracic Cancer|March 20, 2019
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumabOu Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, et al.Cancer Science|October 15, 2019
Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung diseaseHirotsugu Kenmotsu, Kiyotaka Yoh, Keita Mori, et al.Frontiers in Immunology|October 23, 2025
Eosinophils as predictive biomarkers in anti-programmed cell death 1 monotherapy for non-small cell lung cancerTakahiro Uchida, Kazuyuki Nakagome, Kosuke Hashimoto, et al.Chemotherapy|April 7, 2021
Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine CarcinomaKen Naganuma, Hisao Imai, Ou Yamaguchi, et al.Thoracic Cancer|February 19, 2020
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Tomonori Kawasaki, et al.Journal of Cancer Research and Clinical Oncology|January 22, 2025
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancerSatoshi Endo, Hisao Imai, Atsuto Mouri, et al.The Clinical Respiratory Journal|February 18, 2015
An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter reportNoriyuki Enomoto, Kingo Chida, Takafumi Suda, et al.Cancer Medicine|April 18, 2025
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus IpilimumabAtsuto Mouri, Hisao Imai, Satoshi Endo, et al.Medicina (Kaunas, Lithuania)|June 27, 2025
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational StudyYuhei Kurata, Atsuto Mouri, Hisao Imai, et al.Translational Lung Cancer Research|July 11, 2026
The impact of local tumor immune responses on prognosis in resected lung adenocarcinomaYoshinobu Ichiki, Anna Takimoto, Yuri Sugawara, et al.Pageof 10